# Study to Evaluate the Efficacy and Safety of CKD-352

> **NCT04548427** · PHASE3 · COMPLETED · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 283 (actual)

## Conditions studied

- Dry Eye Disease

## Interventions

- **DRUG:** CKD-352
- **DRUG:** Diquafosol Sodium 3%

## Key facts

- **NCT ID:** NCT04548427
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-22
- **Primary completion:** 2021-05-07
- **Final completion:** 2021-05-07
- **Target enrollment:** 283 (ACTUAL)
- **Last updated:** 2021-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04548427

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04548427, "Study to Evaluate the Efficacy and Safety of CKD-352". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04548427. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*